What question did this study set out to answer?

The study aims to evaluate the effects of trf-budesonide on improving kidney function and blood pressure in a child with iga nephropathy.

March 28, 2026Kidney International Reports0 citationsOpen Access

Wcn26-6465 Application of TRF-Budesonide(nefecon) in the Trearment of Pediatric Patient With Iga Nephropathy: A Case Report

XZX Zhu YTYiming Tong YOYan Ouyang

Key Points

The study aims to evaluate the effects of trf-budesonide on improving kidney function and blood pressure in a child with iga nephropathy.
Case report of treatment with trf-budesonide in a pediatric patient already diagnosed with iga nephropathy.
Monitoring of blood pressure and eGFR (estimated glomerular filtration rate) over time.
Statistical analysis of blood pressure and kidney function changes pre- and post-treatment.
Significant reduction in blood pressure observed post-treatment with trf-budesonide (p<0.05).
eGFR improvement noted, with a negative correlation with post-treatment blood pressure (p<0.05).
Treatment suggested to provide nephroprotection, slowing the progression of kidney disease.

Abstract

18/73 13 mmHg (both p<0. 05). eGFR slope -3. 67 0. 34 -1. 39 0. 41 mL/min/1. 73m 2 /yr (p<0. 05) ;UPCR 2. 0 2. 4 2. 0 2. 5 (p=0. 73). Subgroups: NS (n=31): HBP 134 12/78 13 130 9/73 9 (p=0. 06/p=0. 05) ;OBP 150 18/80 17 138 17/73 12 (both p<0. 05) ; eGFR -3. 60 0. 64 -0. 85 0. 75 (p<0. 05). DKD (n=21): HBP 143 14/76 13 134 12/73 11 (p<0. 05/p=0. 29) ;OBP 152 23/77 16 142 20/71 11 (p=0. 09/p=0. 06) ;eGFR -4. 73 0. 75 -3. 55 0. 93 (p=0. 12). eGFR 30 (n=35): HBP 136 13/80 12 129 11/78 9 (p<0. 05/p=0. 36) ;OBP 148 18/81 19 136 17/76 14 (p<0. 05/p=0. 06) ;eGFR -2. 85 0. 52 -0. 51 0. 77 (p<0. 05). eGFR <30 (n=49): HBP 136 12/78 11 130 10/72 9 (both p<0. 05) ;OBP 151 21/76 15 144 18/72 11 (p<0. 05/p=0. 07) ;eGFR -4. 25 0. 49 -2. 02 0. 54 (p<0. 05). eGFR slope correlated negatively with post-HSBP (= -0. 20, p<0. 05, R 2 = 0. 10). By post-HSBP group: A (n=41) -3. 58 0. 43 0. 41 0. 57 (p<0. 05) ;B (n=28) -3. 15 0. 53 -3. 64 0. 69 (p=0. 41) ;C (n=15) -5. 04 1. 35 -4. 96 1. 55 (p=0. 93) ;ANOVA p<0. 05. The mixed model also showed a significant three-way interaction (time treatment post-HSBP, = -0. 19, p<0. 05). Conclusion: ARNI improved BP and eGFR slope in CKD, with consistent effects except in DKD. Improvement was associated with lower post-HSBP, suggesting that BP reduction under ARNI contributes to renoprotection. ARNI provides a potent antihypertensive effect while preserving eGFR through balanced dilation of both afferent and efferent arterioles. These findings indicate that ARNI safely lowers blood pressure even in advanced stages of CKD and may play a beneficial role in slowing CKD progression. I have no potential conflict of interest to disclose. I did not use generative AI and AI-assisted technologies in the writing process.

KI fragen

Bookmark

View Full Paper